Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review
Mihret Tilahun,Yeshimebet kassa,Alemu Gedefie,Melaku Ashagire,Melaku Ashagrie Belete
DOI: https://doi.org/10.2147/IDR.S337611
2021-10-22
Infection and Drug Resistance
Abstract:Mihret Tilahun, Yeshimebet kassa, Alemu Gedefie, Melaku Ashagire Department of Medical Laboratory Sciences, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia Correspondence: Mihret Tilahun Department of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, PO.BOX: 1145, Dessie, Ethiopia Tel +251 920988307 Fax +251 333115250 Email Infections due to multidrug-resistant Enterobacteriaceae have become major international public health problem due to the inadequate treatment options and the historically lagged pace of development of novel antimicrobial drugs. Inappropriate antimicrobial use in humans and animals coupled with increased global connectivity aided to the transmission of drug-resistant Enterobacteriaceae infections. Carbapenems are the medications of choice for extended-spectrum beta-lactamase and AmpC producers, but alternatives are currently needed because carbapenem resistance is increasing globally. This review pointed to discuss emerging drug-resistant Enterobacteriaceae , its epidemiology and novel treatment options for infections, which date back from 2010 to 2019 by searching Google Scholar, PubMed, PMC, Hinari and other different websites. The occurrence of carbapenem-resistant Enterobacteriaceae is reported worldwide with great regional variability. The rise of carbapenem-resistant Enterobacteriaceae poses a threat to all nations. Enzyme synthesis, efflux pumps, and porin mutations are the main methods by which Enterobacteriaceae acquire resistance to carbapenems. The major resistance mechanism among these is enzyme synthesis. Most carbapenem resistance is caused by three enzyme groups: Klebsiella pneumoniae carbapenemase (Ambler class A), metallo-ß-lactamases (Ambler class B), and oxacillinase-48 (Ambler class D). Ceftazidime–avibactam, which was newly licensed for carbapenemase producers, is the most common treatment option for infections. Meropenem–vaborbactam, imipenem–relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam–avibactam are recently reported to be active against carbapenem-resistant Enterobacteriaceae ; and are also in ongoing trials for different populations and combinations with other antibacterial agents. Overall, treatment must be tailored to the patient's susceptibility profile, type and degree of infection, and personal characteristics. Keywords: multidrug resistance, antimicrobial therapy, carbapenemase, Enterobacteriaceae The causative agent of an infectious disease whose incidence is increasing following its appearance in a new host population or whose incidence is increasing in an existing population as a result of long-term changes in its underlying epidemiology or the development of antimicrobial resistance has been defined as an emerging antibiotic-resistant pathogen. 1 Carbapenem-resistant Enterobacteriaceae (CRE) infections result in longer hospital admissions, higher healthcare costs, and increased mortality than carbapenem-susceptible bacterial infections. 2 The Enterobacteriaceae family includes many bacteria that are commonly isolated from clinical cultures, including Escherichia coli, Klebsiella spp., and Enterobacter spp. Because Enterobacteriaceae are a common cause of both community and healthcare-related diseases, they are particularly important in the context of antibiotic resistance. 3 The Enterobacteriaceae family has developed through time and has an innate ability to proliferate by developing resistance to antimicrobial chemicals provided, rendering existing antibacterial ineffective, and emerging as resistant to carbapenem, a last-line antibiotic. 4,5 In the human and animal colons, Enterobacteriaceae is mostly found as part of the normal flora. According to the World Health Organization's antimicrobial resistance report, Enterobacteriaceae resistant to carbapenem are classified as a critical group and developing drug-resistant infections. 6,7 According Centers for Disease Control (CDC) description of the antimicrobial-resistant pathogens, CRE such as Klebsiella species, Escherichia coli ( E.coli ) and Enterobacter species are the most crucial emerging resistance threats in the global. 8 Bacterial infections caused by CRE, which are resistant to all classes of current antimicrobial drugs, have become a serious endpoint in the fight against bacterial infections in public health. 9–11 Furthermore, the rise of carbapenem resistance and rapid dissemination of the Enterobacteriaceae family are referred to as "superbugs bacteria". 12,13 Because of the emergence of the CRE family, therapeutic approaches are n -Abstract Truncated-
pharmacology & pharmacy,infectious diseases